Navigation Links
BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
Date:7/31/2008

BIRMINGHAM, Ala., July 31 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced that its second quarter 2008 financial results will be released on Thursday, August 7, 2008. Following the release, BioCryst will host a conference call and Webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide an update on the Company's programs. The call will be led by Jon P. Stonehouse, BioCryst's Chief Executive Officer, and Stuart Grant, BioCryst's Chief Financial Officer.

The Webcast can be accessed by logging onto http://www.biocryst.com. Please connect to the Website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the Webcast. To participate in the conference call, please dial 1-800-860-2442 (United States) or 1-412-858-4600 (International). No passcode is needed for the call. The audio portion of the Webcast will be archived and available for replay for 14 days.

About BioCryst

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The Company is advancing multiple internal programs toward potential commercialization including forodesine HCl in oncology, BCX-4208 in psoriasis and peramivir in seasonal and life-threatening influenza. BioCryst is collaborating with Mundipharma for the development and commercialization of forodesine HCl in markets across Europe, Asia, Australia and certain neighboring countries. In January 2007, the U.S. Department of Health and Human Services (HHS
'/>"/>

SOURCE BioCryst Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
5. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
6. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Shimadzu Scientific Instruments today announces ... spectrophotometer. Offering wavelength scanning from 190 to 1,100 ... applications in a variety of industries, including environmental, ... UV-1280 enables intuitive operation, while the enhanced validation, ...
(Date:1/22/2015)... Mass (PRWEB) January 21, 2015 Cambridge Semantics, ... Web technology, today announced that 2014 was a record-breaking year ... the capabilities of the Anzo Smart Data Platform and our ... and utilize insights from diverse data which led to record ...
(Date:1/22/2015)... Diego, California (PRWEB) January 22, 2015 ... Promotional Offer to their comprehensive portfolio of Eppendorf ... allows customers to purchase a Centrifuge 5424/5424 R and ... Bundle of either Eppendorf Research plus or Eppendorf Reference ...
(Date:1/22/2015)... Geneva, Switzerland (PRWEB) January 22, 2015 ... for characterized mammalian Research Cell Banks (RCBs) used for ... generated Research Cell Banks will include Next-Generation Sequencing ... cell’s genetic architecture de-risks biologic manufacturing by ensuring the ...
Breaking Biology Technology:Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Cambridge Semantics Announces Record Results for 2014 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2
... Mass., Oct. 9 Boston Scientific,Corporation (NYSE: ... its,CONFIENT(TM) implantable cardioverter defibrillator (ICD). This approval,represents the ... sudden cardiac death (SCD). The CONFIENT ICD, ... to reduce unnecessary right ventricular pacing. This product ...
... Oct. 9 A homegrown New Jersey company ... pedigree of pharmaceuticals everywhere. Secure Symbology, (http://www.securesymbology.com ), ... as an,Honored Finalist as Emerging Business of the ... for its vision to wipe out counterfeit drugs,worldwide. ...
... ; MTAX) management will present at the Biotechnology Industry,Organization (BIO) Investor Forum ... Francisco. The conference will also be webcast live with slides and ... . ... & Investor Conference ...
Cached Biology Technology:Boston Scientific Announces European Approval of Next-Generation Implantable Defibrillator 2Boston Scientific Announces European Approval of Next-Generation Implantable Defibrillator 3Secure Symbology: Making New Jersey Proud While Saving Lives 2
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, the ... eliminate the pain of trying to remember their usernames and ... fused to their smartphones. To assist people who have struggled ... company that created 1U and focuses on redefining identity, announced ...
(Date:12/19/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) ... Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition ... reading feature with the iPhone 5S. It is currently ...
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint ... http://photos.prnewswire.com/prnh/20130307/600769 Based ... 5S, Samsung introduces for the first time a fingerprint ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... identified a gene variation in heart disease patients who appear ... to the point where blood flow to the heart is ... may be one way to better identify patients who are ... Sheps, M.D., a professor and associate chairman of cardiovascular medicine ...
... Diego and PhoenixApril 15, 2008Clinical researchers at Scottsdale Healthcare ... trials that show promise for patients battling cancer. ... the this weeks Annual Meeting of the American Association ... focused on basal cell carcinoma (BCC) and pancreatic cancer. ...
... a century after the last earth-shattering atomic blast shook the ... coral species, however, appear to be locally extinct. These ... team of scientists from Australia, Germany, Italy, Hawaii and the ... of marine life in the atoll. One ...
Cached Biology News:Mental stress reduces blood flow to the heart in patients with gene variation 2Mental stress reduces blood flow to the heart in patients with gene variation 32 new therapies show promise for cancer patients 22 new therapies show promise for cancer patients 3Bikini corals recover from atomic blast 2Bikini corals recover from atomic blast 3
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
Taq DNA polymerase, 10,000U...
... DNA Polymerase is the most thoroughly characterized ... testimony to its overall utility and efficacy. ... ideal for PCR applications. , It ... ,, AmpliTaq DNA Polymerase is a ...
Taq DNA Polymerase (T. aquaticus), 4 x 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying En...
Biology Products: